Clinical Trial Update: Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of panobinostat and sorafenib for metastatic or unresectable liver cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Farydak (panobinostat)
• Nexavar (Sorafenib)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Liver Cancer | Phase 1 | Status: TERMINATED